Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 17/20 | 0.75 |
| ▸ | FPR2 | P25090 | 2/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690192 | 1.00 | KDM1A (0.75) | KDM1AFPR2SIGMAR1 | |
| SCHEMBL6867689 | 0.97 | KDM1A (0.74) | KDM1AFPR2SIGMAR1 | |
| SCHEMBL6865338 | 0.95 | KDM1A (0.75) | KDM1AFPR2SIGMAR1 | |
| SCHEMBL13305180 | 0.90 | KDM1A (0.74) | KDM1AFPR2 | |
| Pyrathiazine SCHEMBL2110244 | 0.88 | KDM1A (0.76) | KDM1A | |
| Pyrathiazine SCHEMBL30184095 | 0.88 | KDM1A (0.76) | KDM1A | |
| SCHEMBL13305171 | 0.88 | CYP2D6 (0.80) | KDM1AFPR2SIGMAR1 | |
| Pyrathiazine SCHEMBL142434 | 0.87 | KDM1A (0.73) | KDM1A | |
| SCHEMBL31673743 | 0.86 | KDM1A (0.85) | KDM1AFPR2SIGMAR1 | |
| SCHEMBL20412109 | 0.86 | KDM1A (0.85) | KDM1AFPR2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IL5, HRH4, TLR5 | KDM1A 1459/4885FPR2 80/4885SIGMAR1 1558/4885 |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | HTR4, HTR3B, HTR5A | KDM1A 3659/4885FPR2 70/4885SIGMAR1 509/4885 |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | KDM1A 3921/4885FPR2 43/4885SIGMAR1 1613/4885 |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | NFATC1, BAX, BCL2 | KDM1A 1810/4885FPR2 153/4885SIGMAR1 4763/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | KDM1A 3824/4885FPR2 47/4885SIGMAR1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.